Cellectis Logo

Cellectis

ISIN: FR0010425595 | Ticker: ALCLS | LEI: 5493000KKX5VQ37Q2W83
Sector: Health CareSub-Industry: Biotechnology
Country: France

About Cellectis

Company Description

Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

Year founded

1999

Served area

Worldwide

Headcount

294

Headquarters

8 Rue de la Croix-Jarry, 75013 Paris – France

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

FR0010425595

LEI

5493000KKX5VQ37Q2W83

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Paris

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.